We measured a2-adrenoreceptor density as well as affinity for and sensitivity to agonist on intact platelets of normotensive and hypertensive subjects before and after physiological increases in plasma catecholamines. In normotensives, posture-induced rises in plasma catecholamines correlated with reduced C2-adrenoreceptor agonist affinity and fewer high affinity state receptors. Platelet aggregation and inhibition of adenylate cyclase by L-epinephrine also was reduced. Hypertensive subjects had similar rises in plasma catecholamines with upright posture, but showed no change in receptor affinity or sensitivity. No change in platelet a2-adrenoreceptor number occurred in-these studies. In vitro incubation with L-epinephrine revealed that platelets from hypertensives had slower desensitization than those from normotensives. Binding studies at different temperatures and with varying sodium concentrations found no thermodynamic or sodium-dependent differences between normotensive and hypertensive groups.
Introduction
The influence ofthe sympathetic nervous system on blood pressure is mediated predominantly by the catecholamines norepinephrine and epinephrine acting at alpha and beta adrenoreceptors. Many prior investigations of the sympathetic nervous system in human hypertension have concentrated on attempts to detect elevated plasma catecholamines in hypertensive subjects. Although these studies varied greatly in design, the data do not support the hypothesis that catecholamine excess is the sole cause of hypertension (1, 2) . However, recent studies have shown that hypertensive subjects have enhanced pressor responsiveness to catecholamine and sympathomimetic amine infusions (3) (4) (5) (6) (7) . These findings are consistent with the proposal that vasoconstrictor alpha adrenoreceptors of hypertensive subjects are more sensitive to catecholamines than are those of normotensives.
Increased responsiveness ofadrenergic receptors may be secondary to an increase in the number of receptors and/or an increase in receptor-effector coupling efficiency. An increase in platelet a2-adrenoreceptor density combined with pressor, cardioacceleratory and proaggregatory hypersensitivity to catecholamines has been reported in orthostatic hypotensive subjects with chronically low circulating catecholamines (8) (9) (10) . However, several reports have found normal numbers of platelet 2-adrenoreceptors in hypertensive subjects (11) (12) (13) , suggesting that the enhanced sensitivity of hypertensives to catecholamines is not associated with an increase in adrenoreceptor number.
We have demonstrated recently that plasma catecholamines inversely regulate platelet a2-adrenoreceptor and lymphocyte #2-adrenoreceptor affinity for and sensitivity to agonists over short time periods in normotensive subjects (14) (15) (16) . Since enhanced pressor sensitivity of hypertensives cannot be attributed to increased a-adrenoreceptor density, we studied agonist regulation of a2-adrenoreceptor agonist affinity and sensitivity in order to determine whether abnormal affinity state regulation is associated with enhanced receptor sensitivity found in hypertension. We report here that hypertensives exhibit a defect in agonist-mediated desensitization of platelet a2-adrenoreceptors in vivo. Platelet isolation. Platelets were isolated from freshly drawn blood for radioligand binding studies as previously described (14) . In binding studies on the effect of varying extracellular sodium concentrations, Nmethyl-D-glucamine was substituted for the sodium in the wash solutions and incubation buffer. For aggregation studies, platelet-rich plasma was diluted with platelet-poor plasma to approximately 300,000 platelets/,l and aggregatory response to I X 10-to I X 10-8 M L-epinephrine and 3 x 10-s to 3 X 10-7 M ADP was determined in a Payton dual channel aggregometer between 45 and 75 min after blood was drawn. Sensitivity to ADP-induced aggregation was expressed as the concentration of ADP necessary to cause biphasic platelet aggregation (17) . Sensitivity to Lepinephrine-induced aggregation was assessed by plotting the slope of the first phase of aggregation against the log of the L-epinephrine concentration from which the concentration of epinephrine producing halfmaximal aggregation (EC5o) was determined graphically. In vitro epinephrine desensitization experiments involved incubation of plateletrich plasma from hypertensives and normotensives with vehicle, I X I0O M and I X 10-7 M L-epinephrine at 250C without agitation. At 30, 60 , and 120 min, aliquots were tested for aggregatory responsiveness to I X 10-1 M L-epinephrine and the slope of the first phase of aggregation was expressed as a percentage of the simultaneous vehicle-incubated sample.
Binding assay. Competition binding using 19 concentrations of 1-epinephrine against 6-10 nM [3H]yohimbine was performed as described previously (14) . Data were analyzed by the weighted, nonlinear, curvefitting procedure based on the law of mass action described by DeLean et al. (18) for average agonist affinity, high and low agonist affinities (one and two binding site curve-fitting), the proportion of receptors in each affinity state, and the total number of receptors. Since the calculated affinity constants are log-normally distributed, mean affinities expressed in the text are the antilog of the mean log affinity constants. Statistical comparisons of affinity constants were made between means and standard deviations of the logarithmic transformations.
Platelet adenylate cyclase assay. Adenylate cyclase activity was measured in lysed platelet preparations by a modification of the method of Johnson (19) . Washed Plasma catecholamine concentrations were determined by a radioenzymatic assay as previously described (20) .
Subjects. Subjects for this study were normotensive and hypertensive males, 20-41 yr of age, who abstained from all medications for at least 2 wk before the study. All procedures in this study were reviewed and approved by the Vanderbilt University Committee for the Protection of Human Subjects. Subjects were admitted to the Elliot V. Newman Clinical
Research Center and after 8 h of overnight bedrest (ONS) a supine blood sample was drawn for plasma catecholamine concentrations and platelet studies. The subjects then ambulated about the ward for 3 h prior to a second blood sample. Platelets isolated from each blood sample were divided into three parts for simultaneous determination of radioligand binding, platelet aggregation and adenylate cyclase assay. Mean age, blood pressure, and heart rate for the subjects are shown in Table I .
Results
Effect of ONS and 3 h of upright posture (3 h Up) on plasma catecholamine concentrations and average platelet a2adreno-receptor agonist affinity. In comparison with ONS, 3 h Up produced a 135% increase in plasma norepinephrine (P < 0.01) and a 70% rise in plasma epinephrine in normal subjects (Table II) .
Similarly, hypertensives showed increases of 113% in plasma Fig. 1 B) subject. After ONS, the platelets of both the normotensive and hypertensive subjects exhibited shallow competition binding curves for the agonist epinephrine. After 3 h Up however, the epinephrine competition binding curve for the normotensive subject was shifted to the right and was steeper. The hypertensive subject showed no change in agonist competition binding after 3 h Up.
In the group of normotensive subjects, the mean affinity of platelet a2-adrenoreceptors for L-epinephrine fell from 0.93±0.15 AM at ONS to 1.84±0.38 MM (P < 0.01) after 3 h Up. In contrast, the hypertensive subjects as a group showed no overall change (ONS, 1. 11+0.21 M, vs. 3 h Up, 0.94±0.13 ,M; not significant).
At 3 h Up, platelet a2-adrenoreceptors from hypertensive subjects exhibited a significantly higher affinity for agonist than those of normotensive subjects (P < 0.05). In normotensives, the change in circulating norepinephrine was significantly correlated with the fall in platelet a2-adrenoreceptor affinity for the agonist, Lepinephrine (n = 10, r = 0.86, P < 0.001). Fig. 2 A depicts the relationship between plasma norepinephrine and the affinity of platelet a2-adrenoreceptors for agonist in each subject after ONS and 3 h Up. In contrast, despite similar rises in plasma catecholamines in the hypertensive subjects, there was no consistent reduction in platelet a2-adrenoreceptor affinity for agonist (n = 16, r = -0.0040, P > 0.2, Fig. 2 Composite competition binding curves generated by computer from the high and low affinity Kd's ( Fig. 3 A) demonstrate a shift to the right in the binding displacement by agonist when the 3 h Up platelet samples of normotensive subjects are compared with ONS. Platelets of hypertensive subjects exhibited a nonsignificant shift to the left over the same time period. In normotensive subjects, the mean proportion of receptors in the high affinity state for agonist fell from 71 to 38% after 3 h Up (P < 0.001) (Fig. 3 B) . In contrast, hypertensive subjects exhibited no change in the proportion ofhigh affinity state receptors despite similar increases in circulating plasma catecholamines. After 3 h Up, platelets from hypertensives had a significantly higher proportion of their receptors in the high affinity state than did normotensives (P < 0.001). Aggregatory sensitivity to L-epinephrine and ADP. In order to determine whether the failure of hypertensives' platelet a2-adrenoreceptors to reduce affinity after agonist exposure was reflected in sensitivity changes, the same platelet samples obtained after ONS and 3 h Up were tested for in vitro aggregatory sensitivity to L-epinephrine and ADP. The EC50's from L-epinephrine dose-response curves at each time point are found in Table III . Aggregatory sensitivity of platelets to L-epinephrine decreased significantly in normotensives after 3 h Up (P < 0.05), while hypertensives did not. After 3 h Up, hypertensives' platelets were significantly more sensitive to L-epinephrine-induced-aggregation than were normotensives (P < 0.02). These findings agree well by regression analysis with the changes in agonist affinity found in simultaneous binding experiments (r = 0.70, P < 0.01).
The ONS and 3 h Up from normotensive and hypertensive subjects, we determined the EC0.5 (Table IV) .
After 3 h Up, platelets from normotensive subjects showed a significant increase in the ECO.5. In contrast, platelets from hypertensives exhibited no change in the ability of L-epinephrine to inhibit adeny!ate cyclase and, at the 3 h Up sampling time,
were significantly more sensitive to L-epinephrine than normotensives' platelets. The magnitude and direction of changes in L-epinephrine-inhibited adenylate cyclase are consistent with the changes measured by the mean receptor affinity for L-epinephrine and by the EC5o for L-epinephrine-induced aggregation.
In vitro desensitization ofnormotensive's and hypertensive's platelet a2-adrenoreceptors. In order to examine more closely the differences in agonist desensitization of platelet a2-adrenoreceptors between normotensives and hypertensives, we measured the effect ofin vitro exposure of platelets to L-epinephrine on L-epinephrine-stimulated aggregation (Table V) . Platelet-rich plasma from normotensive and hypertensive subjects was incubated at 25°C without agitation with 1 X 10- -TAS0. Table VI shows the thermodynamic parameters derived from normotensive and hypertensive subjects' platelet a2-adrenoreceptor agonist and antagonist binding. These data indicate that the thermodynamic driving forces for agonist binding are the AH0, which is opposed by thermodynamically unfavorable decreases in entropy. In contrast, antagonist binding is driven by entropy. The absence of a large difference in thermodynamic driving forces provides evidence against the existence of marked differences in receptor-ligand and/or receptor-G-protein interaction between platelet a2-adrenoreceptors from normotensive and hypertensive subjects.
Influence ofsodium concentration on the agonist affinity of platelet a_-adrenoreceptors. Platelet a2-adrenoreceptor affinity for agonist has been shown to be inversely proportional to the sodium concentration (21, 22) . Since the effect ofsodium appears to be exerted on the internal side of the membrane (22) and hypertensive subjects have been shown to exhibit altered membrane sodium fluxes (23, 24) , we examined the influence of varying sodium concentration on hypertensives' and normotensives' platelet a2-adrenoreceptor affinity for agonist (Fig. 4) .
Lower assay sodium concentrations produced higher mean affinity constants for intact platelet a2-adrenoreceptor agonist binding without changing the proportion of receptors in the high affinity state (analysis of variance: F3,21 = 539.0, P < 0.0005).
The platelets from five hypertensive subjects exhibited no significant difference in agonist binding affinity at any assay sodium concentration when compared with five normotensive subjects (analysis of variance: F1.8 = 0.756, P > 0.5). The proportion of receptors with high affinity for agonist did not differ between groups with mean±SEM of 75±6% at 1 mM Na+, 79±4% at 10 mM Na+, 78±5% at 30 mM Na+ and 76±6% at 100 mM Na+. These data reduce the possibility that an altered sodium "site" on the a2-adrenoreceptor characterizes essential hypertension and is responsible for the defect in agonist-mediated desensitization.
Discussion
These studies demonstrate that, in normotensive subjects, physiological increases in plasma catecholamines acutely regulate platelet a2-adrenoreceptor affinity for and sensitivity to agonist. (21, 22, 24) . In rabbit platelet membrane preparations, elevated GTP and sodium concentrations lower the affinity of platelet 02-adrenoreceptors for agonists (29) ; GTP, by shifting high agonist affinity site binding to low affinity sites, and sodium by inducing a parallel rightward shift ofthe agonist binding without alterations in the proportion of receptors in the high affinity state. Using intact human platelets, our studies confirmed the shift in agonist binding affinity caused by increasing sodium concentrations and found no change in the proportion of receptors in the high affinity state in either normotensives or hypertensives. Because of the parallel shift in affinity and the lack of differences between normotensives and hypertensives, the possibility that an alteration in the a2-adrenoreceptor "sodium site" occurs in hypertension is lessened.
Another potential cause for the defect in agonist-mediated a2-adrenoreceptor desensitization in hypertensives is an alteration in the receptor and/or receptor-guanine nucleotide regulatory protein interaction. Changes in structure of these molecules or alterations in their binding to each other might have resulted in thermodynamic differences in agonist and antagonist binding between hypertensives and normotensives. However, similar to the results found in the fl-adrenergic system (30, 31), we determined that agonist binding by the a2-adrenoreceptor of intact platelets was temperature sensitive and driven by large decreases in enthalpy, whereas antagonist binding showed little change with temperature and was driven by positive changes in entropy. We found no difference in the thermodynamic driving forces for agonist and antagonist binding between platelet a2-adrenoreceptors from these subjects when the platelet samples were drawn after ONS. These results are consistent with, but do not prove, the hypothesis that no gross structural change in a2-adrenoreceptors and/or their associated guanine nucleotide regulatory protein differentiates hypertensives from normotensives.
These studies have decreased the possibility that either sodium concentration differences or receptor-G-protein changes underlie the defect in agonist-mediated platelet a2-adrenoreceptor desensitization found in hypertensive subjects. Another potential site for this defect is an alteration in membrane "microviscosity" which may secondarily affect receptor-modulating mechanisms. An increased platelet membrane microviscosity has been described in spontaneously hypertensive rats and ascribed either to protein (32) or to fatty acid (33) constituents of the membrane. The fatty acid contents of platelet and red cell membranes appear to be genetically determined and associated with either a family history or the development of hypertension in rats and men (34, 35) . Exactly how these membrane alterations interact with agonist-mediated adrenergic receptor desensitization and whether they may be the source ofthe defect identified in human essential hypertension remains to be elucidated.
In summary, in normotensive human subjects we have identified an agonist-induced reduction in platelet a2-adrenoreceptor affinity for agonist which is characterized by a reduction in the proportion of receptors in the high affinity state and is correlated with a fall in receptor sensitivity. In contrast, hypertensive subjects failed to exhibit changes in a2-adrenoreceptor agonist affinity or sensitivity when exposed to the same in vivo stimuli. There were no significant differences between normo-tensives and hypertensives in the number of a2-adrenoreceptors per platelet, the rise in plasma catecholamines after 3 h Up, the thermodynamic driving forces for agonist and antagonist binding and the influence ofsodium on platelet a2-adrenoreceptor agonist affinity. The precise molecular basis for the defect in agonistmediated a2-adrenoreceptor desensitization in hypertension remains to be identified. We conclude that essential hypertension is characterized by a defect in agonist-mediated platelet a2-adrenoreceptor desensitization and postulate that this defect may be related to the hyperresponsiveness of hypertensives to adrenergic pressor agents.
